Fig. 6.
UC/PL-MSCs inhibit MRTF-A nuclear localization in HIMFs. HIMFs were treated with TGF-β1 (5 ng/mL) and co-cultured with or without UC/PL-MSCs at 2 × 105 cells/insert for 48 h and then stained with MRTF-A antibodies and rhodamine-phalloidin and counterstained with Hoechst. A (A–D) no treatment; (E–H) treatment with TGF-β1; (I-L) treatment with TGF-β1 and PL-MSCs; (M–P) treatment with TGF-β1 and UC-MSCs. a, e, i, m Enlarged images of the region (within the white box of A, E, I, and M, each). B The nuclear-to-cytoplasmic ratio of MRTF-A was determined for each condition as described in the “Methods” section. Data are expressed as the means ± SEM. #P < 0.05 and ##P < 0.01 versus the untreated control; **P < 0.01 and ***P < 0.001 versus the TGF-β1 treatment only; NS, not significant. Scale bars, 100 μm; original magnification, × 200 (A)